Ann: NYR Signs Strategic Partnership with US Brain Injury Company, page-28

2 years time it will be in phase 3. To say it’s worth 12 million market cap on phase 3 when you’re looking more than a billion dollar dollar market cap. You’re off by 1000 percent in 2 years on its target market of 60 billion dollars of potential revenue on the first drug of its type. Smiteoff wherever this goes short term doesn’t matter come after GLP next month because it’s straight into human trials which are already heavily de risked on safety and efficacy. Going to run either way now that it fully funded well into phase 2. Cash is king